5-Lipoxygenase deficiency reduces hepatic inflammation and tumor necrosis factor α-induced hepatocyte damage in hyperlipidemia-prone apoe-null mice

Hepatology

Volumn 51, Issue 3, 2010, Pages 817-827

  Martínez Clemente, Marcos ^a   Ferŕe, Nat̀alia ^a   Gonźalez Ṕeriz, Ana ^a,b   Ĺopez Parra, Marta ^a   Horrillo, Raquel ^a   Titos, Esther ^a,b   Moŕan Salvador, Eva ^a   Miquel, Rosa ^a   Arroyo, Vicente ^a,b   Funk, Colin D ^c   Cl̀aria, Joan ^a,b  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

^c QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

5 HYDROXYICOSATETRAENOIC ACID; ADIPONECTIN; ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN E; ARACHIDONATE 5 LIPOXYGENASE; CASPASE 3; DACTINOMYCIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN RECEPTOR SUBSTRATE 1; INTERLEUKIN 18; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; RECOMBINANT HUMAN INSULIN; STRESS ACTIVATED PROTEIN KINASE; TUMOR NECROSIS FACTOR ALPHA;

ADIPOSE TISSUE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CELL ISOLATION; CELL SURVIVAL; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE PREDISPOSITION; DOWN REGULATION; DRUG INHIBITION; FATTY LIVER; HEART PROTECTION; HYPERLIPIDEMIA; IMMUNOHISTOCHEMISTRY; INFLAMMATION; INFLAMMATORY INFILTRATE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIVER CELL DAMAGE; LIVER FIBROSIS; MACROPHAGE; METABOLIC DISORDER; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION;

ANIMALS; APOLIPOPROTEINS E; ARACHIDONATE 5-LIPOXYGENASE; HEPATITIS; HEPATOCYTES; HYPERLIPIDEMIAS; MICE; MICE, KNOCKOUT; TUMOR NECROSIS FACTOR-ALPHA;

EID: 77950619121     PISSN: 02709139     EISSN: 15273350     Source Type: Journal    
DOI: 10.1002/hep.23463     Document Type: Article

References (39)

1. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
2. Sanyal AJ. Mechanisms of disease: pathogenesis of nonalcoholic fatty liver disease. Nat Clin Pract Gastroenterol Hepatol 2005;2:46-53.
3. Gastaldelli A, Kozakova M, Højlund K, Flyvbjerg A, Favuzzi A, Mitrakou A, et al.; The RISC Investigators. Fatty liver is associated with insulin resistance, risk of coronary heart disease, and early atherosclerosis in a large European population. HEPATOLOGY 2009;49:1537-1544.
4. Pendino GM, Mariano A, Surace P, Caserta CA, Fiorillo MT, Amante A, et al.; ACE Collaborating Group. Prevalence and etiology of altered liver tests: a population-based survey in a Mediterranean town. HEPATOLOGY 2005;41:1151-1159.
5. Koruk M, Sava̧s MC, Yilmaz O, Tayşi S, Karakok M, Gündoĝdu C, et al. Serum lipids, lipoproteins and apolipoproteins levels in patients with nonalcoholic steatohepatitis. J Clin Gastroenterol 2003;37:177-182. (Pubitemid 36875582)
6. Wouters K, van Gorp PJ, Bieghs V, Gijbels MJ, Duimel H, Lütjohann D, et al. Dietary cholesterol, rather than liver steatosis, leads to hepatic inflammation in hyperlipidemic mouse models of non-alcoholic steatohepatitis. HEPATOLOGY 2008;48:474-486.
7. Ferré N, Mart́nez-Clemente M, López-Parra M, González-Périz A, Hor-rillo R, Planagumà A, et al. Increased susceptibility to exacerbated liver injury in hypercholesterolemic ApoE-deficient mice: potential involvement of oxysterols. Am J Physiol 2009;296:G553-G562.
8. Samuelsson B, Dahlen SE, Lindgren JA, Rouzer CA, Serhan CN. Leuko-trienes and lipoxins: structures, biosynthesis, and biological effects. Science 1987;237:1171-1176.
9. Funk CD. Prostaglandins and leukotrienes: advances in eicosanoid biology. Science 2001;294:1871-1875.
10. Titos E, Clària J, Bataller R, Bosch-Marcé M, Ginès P, Jiménez W, et al. Hepatocyte-derived cysteinyl leukotrienes modulate vascular tone in experimental cirrhosis. Gastroenterology 2000;119:794-805.
11. Titos E, Clària J, Planagumà A, López-Parra M, Villamor N, Párrizas M, et al. Inhibition of 5-lipoxygenase induces cell growth arrest and apoptosis in rat Kupffer cells: implications for liver fibrosis. FASEB J 2003;17:1745-1747.
12. Titos E, Clària J, Planagumà A, López-Parra M, González-Périz A, Gaya J, et al. Inhibition of 5-lipoxygenase-activating protein abrogates experimental liver injury: role of Kupffer cells. J Leukoc Biol 2005;78:871-878.
13. Horrillo R, Planagumà A, González-Périz A, Ferré N, Titos E, Miquel R, et al. Comparative protection against liver inflammation and fibrosis by a selective cyclooxygenase-2 inhibitor and a nonredox-type 5-lipoxygenase inhibitor. J Pharmacol Exp Ther 2007;323:778-786.
14. López-Parra M, Titos E, Horrillo R, Ferré N, González-Périz A, Mart́nez-Clemente M, et al. Regulatory effects of arachidonate 5-lipoxygenase on hepatic microsomal TG transfer protein activity and VLDL-triglyceride and apoB secretion in obese mice. J Lipid Res 2008;49:2513-2523.
15. Zhao L, Moos MP, Gräbner R, Pédrono F, Fan J, Kaiser B, et al. The 5-lipoxygenase pathway promotes pathogenesis of hyperlipidemia-depen- dent aortic aneurysm. Nat Med 2004;10:966-973.
16. Mehrabian M, Allayee H, Wong J, Shi W, Wang XP, Shaposhnik Z, et al. Identification of 5-lipoxygenase as a major gene contributing to atherosclerosis susceptibility in mice. Circ Res 2002;91:120-126.
17. Hlawaty H, Jacob MP, Louedec L, Letourneur D, Brink C, Michel JB, et al. Leukotriene receptor antagonism and the prevention of extracellular matrix degradation during atherosclerosis and in-stent stenosis. Arterio-scler Thromb Vasc Biol 2009;29:518-524.
18. González-Périz A, Horrillo R, Ferré N, Gronert K, Dong B, Morán-Sal-vador E, et al. Obesity-induced insulin resistance and hepatic steatosis are alleviated by omega-3 fatty acids: a role for resolvins and protectins. FASEB J 2009;23:1946-1957.
19. Austyn JM, Gordon S. F4/80, a monoclonal antibody directed specifically against the mouse macrophage. Eur J Immunol 1981;11:805-815.
20. Carroll NV, Longley RW, Roe JH. The determination of glycogen in liver and muscle by use of anthrone reagent. J Biol Chem 1956;220:583-593.
21. Hirosumi J, Tuncman G,ChangL,Görgün CZ, Uysal KT, MaedaK,etal. A central role for JNK in obesity and insulin resistance. Nature 2002;420: 333-336.
22. Trayhurn P. Endocrine and signalling role of adipose tissue: new perspectives on fat. Acta Physiol Scand 2005;184:285-293.
23. Tilg H, Moschen AR. Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol 2006;6:772-783.
24. Xu Y, Bialik S, Jones BE, Iimuro Y, Kitsis RN, Srinivasan A, et al. NF-kappaB inactivation converts a hepatocyte cell line TNF-alpha response from proliferation to apoptosis. Am J Physiol 1998;275:1058-1066.
25. Sun B, Karin M. NF-kappaB signaling, liver disease and hepatoprotective agents. Oncogene 2008;20:6228-6244.
26. Sánchez-Galán E, Gómez-Hernández A, Vidal C, Mart́n-Ventura JL, Blanco-Colio LM, Muñoz-Garća B, et al. Leukotriene B4 enhances the activity of nuclear factor-kappaB pathway through BLT1 and BLT2 receptors in atherosclerosis. Cardiovasc Res 2009;81:216-225.
27. Bäck M, Bu DX, Bränström R, Sheikine Y, Yan ZQ, Hansson GK. Leu-kotriene B4 signaling through NF-kappaB-dependent BLT1 receptors on vascular smooth muscle cells in atherosclerosis and intimal hyperplasia. Proc Natl Acad Sci USA 2005;102:17501-17506.
28. Kuipers F, Jong MC, Lin Y, Eck M, Havinga R, Bloks V, et al. Impaired secretion of very low density lipoprotein-triglycerides by apolipoprotein E-deficient mouse hepatocytes. J Clin Invest 1997;100:2915-2922.
29. Mensenkamp AR, Van Luyn MJ, Havinga R, Teusink B, Waterman IJ, Mann CJ, et al. The transport of triglycerides through the secretory pathway of hepatocytes is impaired in apolipoprotein E deficient mice. J Hepa-tol 2004;40:599-606.
30. Efsen E, Bonacchi A, Pastacaldi S, Valente AJ, Wenzel UO, Tosti-Guerra C, Pinzani M, et al. Agonist-specific regulation of monocyte chemoattrac-tant protein-1 expression by cyclooxygenase metabolites in hepatic stellate cells. HEPATOLOGY 2001;33:713-721.
31. Zamara E, Galastri S, Aleffi S, Petrai I, Aragno M, Mastrocola R, et al. Prevention of severe toxic liver injury and oxidative stress in MCP-1-deficient mice. J Hepatol 2007;46:230-238.
32. Matsumaru K, Ji C, Kaplowitz N. Mechanisms for sensitization to TNF-induced apoptosis by acute glutathione depletion in murine hepatocytes. HEPATOLOGY 2003;37:1425-1434.
33. Tsutsui H, Matsui K, Okamura H, Nakanishi K. Pathophysiological roles of interleukin-18 in inflammatory liver diseases. Immunol Rev 2000;174: 192-209.
34. Xu A, Wang Y, Keshaw H, Xu LY, Lam KS, Cooper GJ. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J Clin Invest 2003;112:91-100.
35. Kamada Y, Tamura S, Kiso S, Matsumoto H, Saji Y, Yoshida Y, et al. Enhanced carbon tetrachloride-induced liver fibrosis in mice lacking adi-ponectin. Gastroenterology 2003;125:1796-1807.
36. Tacke F, Luedde T, Trautwein C. Inflammatory pathways in liver ho-meostasis and liver injury. Clin Rev Allergy Immunol 2009;36:4-12.
37. Tiegs G, Wendel A. Leukotriene-mediated liver injury. Biochem Pharmacol 1988;37:2569-2573.
38. El-Swefy S, Hassanen SI. Improvement of hepatic fibrosis by leukotriene inhibition in cholestatic rats. Ann Hepatol 2009;8:41-49.
39. Muller D, Enderle GJ, Low O, Dietze E, Krell H. Bile ductular proliferation and altered leukotriene elimination in thioacetamide-induced fibrosis of rat liver. J Hepatol 1996;25:547-553.